{"id":16285,"date":"2012-04-01T17:00:39","date_gmt":"2012-04-01T17:00:39","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=16285"},"modified":"2012-07-26T11:22:58","modified_gmt":"2012-07-26T11:22:58","slug":"19th-conference-on-retroviruses-and-opportunistic-infections-croi","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/16285","title":{"rendered":"19th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 March 2012"},"content":{"rendered":"<h2><strong><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-16371\" title=\"CROI-logo-5-150x142\" src=\"https:\/\/i-base.info\/htb\/files\/2012\/04\/CROI-logo-5-150x142.png\" alt=\"\" width=\"150\" height=\"142\" \/>Introduction<\/strong><\/h2>\n<p><strong>The Conference on Retroviruses and Opportunistic Infections (CROI) conference is probably the most important annual scientific HIV meeting and it is also one of the most accessible for people who are unable to attend the meeting.<\/strong><\/p>\n<p>Most of the presentations are available to watch free online without registration. This includes web casts of the opening lectures, oral presentations and poster discussions.<\/p>\n<p>Abstracts and PDF files for many of the full posters are also online.<\/p>\n<p><a href=\"http:\/\/retroconference.org\">http:\/\/retroconference.org<\/a><\/p>\n<p>With over 1100 studies presented, we will split coverage over two issues of HTB. This issue includes reports on cure research, antiretrovirals, paediatrics, prevention studies and some hepatitis coinfection. The next issue will include PMTCT, women\u2019s health, treatment access, TB, opportunistic infections, side effects and other complications. Some of these early reports will be posted online prior to the print edition.<\/p>\n<p>This issue includes:<\/p>\n<ul>\n<li><a title=\"Permanent link to Cure research takes centre stage: proof of concept for activating the latent reservoir\" href=\"https:\/\/i-base.info\/htb\/16287\" rel=\"bookmark\">Cure research takes centre stage: proof of concept for activating the latent reservoir<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Quad fixed-dose integrase combination: phase 3 studies at week 48\" href=\"https:\/\/i-base.info\/htb\/16289\" rel=\"bookmark\">Quad fixed-dose integrase combination: phase 3 studies at week 48<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Dolutegravir studies continue to show promise\" href=\"https:\/\/i-base.info\/htb\/16291\" rel=\"bookmark\">Dolutegravir studies continue to show promise<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Tenofovir prodrug: 10 day monotherapy study sets dose at 25 mg for easier coformulation\" href=\"https:\/\/i-base.info\/htb\/16295\" rel=\"bookmark\">Tenofovir prodrug: 10 day monotherapy study sets dose at 25 mg for easier coformulation<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Paediatric formulations of ARVs: including an exciting new class\" href=\"https:\/\/i-base.info\/htb\/16308\" rel=\"bookmark\">Paediatric formulations of ARVs: including an exciting new class<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Lower malaria risk in children receiving lopinavir\/ritonavir-based compared to NNRTI-based ART\" href=\"https:\/\/i-base.info\/htb\/16313\" rel=\"bookmark\">Lower malaria risk in children receiving lopinavir\/ritonavir-based compared to NNRTI-based ART<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to High prevalence of d4T-associated lipodystrophy including lipoatrophy in children\" href=\"https:\/\/i-base.info\/htb\/16318\" rel=\"bookmark\">High prevalence of d4T-associated lipodystrophy including lipoatrophy in children<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Lopinavir\/ritonavir monotherapy in children\" href=\"https:\/\/i-base.info\/htb\/16321\" rel=\"bookmark\">Lopinavir\/ritonavir monotherapy in children<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Stopping treatment after early ART in infants\" href=\"https:\/\/i-base.info\/htb\/16324\" rel=\"bookmark\">Stopping treatment after early ART in infants<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to PrEP: PK modeling of daily TDF\/FTC (Truvada) provides close to 100% protection against HIV infection\" href=\"https:\/\/i-base.info\/htb\/16327\" rel=\"bookmark\">PrEP: PK modeling of daily TDF\/FTC (Truvada) provides close to 100% protection against HIV infection<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Risk of HIV reinfection may be similar to risk of initial HIV infection\" href=\"https:\/\/i-base.info\/htb\/16330\" rel=\"bookmark\">Risk of HIV reinfection may be similar to risk of initial HIV infection<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Case report: homozygous CCR5 delta-32 protection overcome by infection with X4 virus\" href=\"https:\/\/i-base.info\/htb\/16332\" rel=\"bookmark\">Case report: homozygous CCR5 delta-32 protection overcome by infection with X4 virus<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to No association between atazanavir and MI or stroke in D:A:D study\" href=\"https:\/\/i-base.info\/htb\/16334\" rel=\"bookmark\">No association between atazanavir and MI or stroke in D:A:D study<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Hepatitis C coinfection studies\" href=\"https:\/\/i-base.info\/htb\/16336\" rel=\"bookmark\">Hepatitis C coinfection studies<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Herpes Zoster vaccine safe and effective in HIV positive people\" href=\"https:\/\/i-base.info\/htb\/16280\" rel=\"bookmark\">Herpes Zoster vaccine safe and effective in HIV positive people<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to High dose flu vaccine improves antibody responses in HIV positive people\" href=\"https:\/\/i-base.info\/htb\/16277\" rel=\"bookmark\">High dose flu vaccine improves antibody responses in HIV positive people<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Introduction The Conference on Retroviruses and Opportunistic Infections (CROI) conference is probably the most important annual scientific HIV meeting and it is also one of the most accessible for people who are unable to attend the meeting. Most of the &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[12,66],"class_list":["post-16285","post","type-post","status-publish","format-standard","hentry","category-conference-reports","tag-conference-index","tag-croi-2012"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/16285","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=16285"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/16285\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=16285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=16285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=16285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}